439 related articles for article (PubMed ID: 25394855)
1. The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
Jeng JS; Sun Y; Lee JT; Lin RT; Chen CH; Po HL; Lin HJ; Liu CH; Sun MH; Sun MC; Chern CM; Lien LM; Chiu HC; Hu HH; Chiou HY; Chen ST; Ma H; Hsu CY;
Int J Stroke; 2015 Jan; 10(1):123-7. PubMed ID: 25394855
[TBL] [Abstract][Full Text] [Related]
2. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
Hong KS; Kim BJ; Lee JY; Kwon SU;
Int J Stroke; 2015 Oct; 10(7):1153-8. PubMed ID: 26044566
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
Lee YS; Bae HJ; Kang DW; Lee SH; Yu K; Park JM; Cho YJ; Hong KS; Kim DE; Kwon SU; Lee KB; Rha JH; Koo J; Han MG; Lee SJ; Lee JH; Jung SW; Lee BC; Kim JS
Cerebrovasc Dis; 2011; 32(1):65-71. PubMed ID: 21613787
[TBL] [Abstract][Full Text] [Related]
5. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Toyoda K; Uchiyama S; Hoshino H; Kimura K; Origasa H; Naritomi H; Minematsu K; Yamaguchi T;
Int J Stroke; 2015 Feb; 10(2):253-8. PubMed ID: 25487817
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
Lee WH; Chu CY; Hsu PC; Su HM; Lin TH; Voon WC; Lai WT; Sheu SH
Thromb Res; 2013 Aug; 132(2):190-5. PubMed ID: 23433530
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Li X; Zhou G; Zhou X; Zhou S
J Neurol Sci; 2013 Sep; 332(1-2):92-6. PubMed ID: 23871093
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis.
Tan L; Margaret B; Zhang JH; Hu R; Yin Y; Cao L; Feng H; Zhang Y
J Stroke Cerebrovasc Dis; 2015 May; 24(5):930-8. PubMed ID: 25804574
[TBL] [Abstract][Full Text] [Related]
9. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Takahashi S; Mizuno O; Sakaguchi T; Yamada T; Inuyama L
Adv Ther; 2014 Jan; 31(1):118-29. PubMed ID: 24385407
[TBL] [Abstract][Full Text] [Related]
10. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
Lee JH; Cha JK; Lee SJ; Ha SW; Kwon SU
Eur J Neurol; 2010 Mar; 17(3):434-42. PubMed ID: 19922458
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
12. Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
Johnston SC; Amarenco P; Albers GW; Denison H; Easton JD; Held P; Jonasson J; Minematsu K; Molina CA; Wong LK
Int J Stroke; 2015 Dec; 10(8):1304-8. PubMed ID: 26311628
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
Farrant M; Easton JD; Adelman EE; Cucchiara BL; Barsan WG; Tillman HJ; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Zhao W; Pauls K; Walsh KB; Martí-Fàbregas J; Bernstein RA; Johnston SC
JAMA Netw Open; 2019 Sep; 2(9):e1910769. PubMed ID: 31490536
[TBL] [Abstract][Full Text] [Related]
14. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Goldenberg NA; Krantz MJ; Hiatt WR
Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antiplatelet and antithrombotic therapy for secondary prevention of ischemic stroke in patients with peripheral artery disease: population-based follow-up study in Taiwan.
Lee WH; Chu CY; Hsu PC; Su HM; Lin TH; Voon WC; Lai WT; Sheu SH
Circ J; 2013; 77(4):1046-52. PubMed ID: 23269006
[TBL] [Abstract][Full Text] [Related]
17. Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.
Ueda H; Kido A; Matsuhisa S; Asawa K; Yoshida N; Tsujimoto M; Sasaki Y; Kuga Y; Yamasaki M; Ueda K; Shinohara S; Nishida Y
Am Heart J; 2016 Mar; 173():134-42. PubMed ID: 26920606
[TBL] [Abstract][Full Text] [Related]
18. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR; Money SR; Brass EP
J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons.
Huang HP; Lin WH; Chen SG; Chen LZ; Chen MY; Che CH
Mol Neurobiol; 2017 Mar; 54(2):1456-1466. PubMed ID: 26846361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
